background bipolar disorder is a common psychiatric disorder with a massive psychological and social burden. research indicates that treatment adherence is not good in these patients. the families’ knowledge about the disorder is fundamental for managing their patients’ disorder. the purpose of the present study was to investigate the knowledge of the family members of a sample of iranian patients with bipolar i disorder (bd-i) and to explore the potential reasons for treatment non-adherence. methods this study was conducted by qualitative content analysis. in-depth interviews were held and open-coding inductive analysis was performed. a thematic content analysis was used for the qualitative data analysis. results the viewpoints of the family members of the patients were categorized in five themes, including knowledge about the disorder, information about the medications, information about the treatment and the respective role of the family, reasons for pharmacological treatment non-adherence, and strategies applied by families to enhance treatment adherence in the patients. the research findings showed that the family members did not have enough information about the nature of bd-i, which they attributed to their lack of training on the disorder. the families did not know what caused the recurrence of the disorder and did not have sufficient knowledge about its prescribed medications and treatments. also, most families did not know about the etiology of the disorder. conclusion the lack of knowledge among the family members of patients with bd-i can have a significant impact on relapse and treatment non-adherence. these issues need to be further emphasized in the training of patients’ families. the present findings can be used to re-design the guidelines and protocols in a way to improve treatment adherence and avoid the relapse of bd-i symptoms.
learn about nimh research on bipolar disorder. find resources on the signs and symptoms of bipolar disorder, types, and potential treatments and therapies.
researchers find first strong genetic risk factor for disorder
engaging people with bipolar disorder and translating their experiences into scientific research will help move from hope to real improvements in treatment.
patients from across the country will be recruited to take part in a major trial examining a new treatment for bipolar disorder.
faculty members david bond, md, phd; and piper meyer-kalos, phd, lp; are basing the blueprint on an existing model, hoping to fill current diagnosis/treatment gaps.
find out about bipolar disorder, including symptoms, how it's diagnosed and treatments.
how psychologists’ understanding of bipolar disorder has changed over the past 3 decades and how those changes have led to earlier and more accurate diagnosis and increasingly personalized treatments.
baylor college of medicine received nearly $10 million in funding from the nih brain initiative to study effective treatments for the depressive phase...
this mental health condition causes extreme mood swings that include emotional highs, called mania, and lows, known as depression.
bipolar disorder is a mental illness characterized by extreme mood swings, including episodes of mania and depression. these mood swings can affect a person
bipolar disorder is a mood disorder that can cause intense mood swings. it's also called manic depression. learn about the types, symptoms, treatment, and more.
explore innovative treatments for bipolar disorder mood swings and energy shifts. discover new hope for managing this challenging condition.
learn about bipolar disorder, including types, symptoms, and treatment options
backgroundbipolar disorder (bd) is predominantly treated with psychotropic drugs, but bd is a complex medical condition and the contribution of psychotropic ...
bipolar disorder treatment continues to improve. here are the latest findings.
bipolar disorders (bds) are recurrent and sometimes chronic disorders of mood that affect around 2% of the world’s population and encompass a spectrum between severe elevated and excitable mood states (mania) to the dysphoria, low energy, and despondency of depressive episodes. the illness commonly starts in young adults and is a leading cause of disability and premature mortality. the clinical manifestations of bipolar disorder can be markedly varied between and within individuals across their lifespan. early diagnosis is challenging and misdiagnoses are frequent, potentially resulting in missed early intervention and increasing the risk of iatrogenic harm. over 15 approved treatments exist for the various phases of bipolar disorder, but outcomes are often suboptimal owing to insufficient efficacy, side effects, or lack of availability. lithium, the first approved treatment for bipolar disorder, continues to be the most effective drug overall, although full remission is only seen in a subset of patients. newer atypical antipsychotics are increasingly being found to be effective in the treatment of bipolar depression; however, their long term tolerability and safety are uncertain. for many with bipolar disorder, combination therapy and adjunctive psychotherapy might be necessary to treat symptoms across different phases of illness. several classes of medications exist for treating bipolar disorder but predicting which medication is likely to be most effective or tolerable is not yet possible. as pathophysiological insights into the causes of bipolar disorders are revealed, a new era of targeted treatments aimed at causal mechanisms, be they pharmacological or psychosocial, will hopefully be developed. for the time being, however, clinical judgment, shared decision making, and empirical follow-up remain essential elements of clinical care. this review provides an overview of the clinical features, diagnostic subtypes, and major treatment modalities available to treat people with bipolar disorder, highlighting recent advances and ongoing therapeutic challenges.
what is new in research on bipolar disorder?
bipolar disorder is a chronic mood disorder that causes intense shifts in mood, energy levels and behavior. manic episodes are the main sign of the co
va hsr&d research topics
many people think that participating in a research study means they will get better treatment for their condition. while this may be true, it’s important to remember that a research … continued
other mental illness diagnoses, taking psychotropic medication (prescribed to treat those illnesses, and specific health service use patterns are strong indicators of bipolar disorder, show researchers from the university of manchester and keele university. the findings – published in the british journal of general practice – will enable do...
for people with bipolar disorder, a new way to measure the impact of treatment may be to measure the size of the “spikes” in their measures of mood and mania
web site created using create-react-app
learn how bipolar disorder treatment, including medication, therapy, and lifestyle changes, can help you manage symptoms and improve your quality of life.
bipolar disorder is a medical condition characterized by extreme mood swings that affect how people think, behave and function.
bipolar ii disorder is characterised by a pattern of depressive episodes and hypomanic episodes, which are less severe than full-blown mania.
this literature review focuses on randomized controlled trials of psychotherapy for bipolar disorder. evidence-based psychotherapies are shown to play an important role in the development of skills needed to manage the persistent and lifelong consequences of bipolar disorder.
bipolar disorders are common, recurrent mental health conditions of variable severity that are difficult to diagnose. affected individuals have higher rates of other mental health disorders, substance use disorders, and comorbid chronic medical illnesses. new diagnostic criteria and specifiers with attention on mixed features and anxious distress aid the physician in recognizing episode severity and prognosis. physicians should consider bipolar disorder in any patient presenting with depression. pharmacotherapy with mood stabilizers, such as lithium, anticonvulsants, and antipsychotics, is a first-line treatment that should be continued indefinitely because of the risk of patient relapse. active lifestyle approaches include good nutrition, exercise, sleep hygiene, and proper weight management. monotherapy with antidepressants is contraindicated during episodes with mixed features, manic episodes, and in bipolar i disorder. ongoing management involves monitoring for suicidal ideation, substance use disorders, treatment adherence, and recognizing medical complications of pharmacotherapy. psychotherapy is a useful adjunct to pharmacotherapy. patients and their support systems should be educated about the chronic nature of this illness, possible relapse, suicidality, environmental triggers (e.g., seasonal light changes, shift work, other circadian disruption), and the effectiveness of early intervention to reduce complications.
bipolar disorder is a serious mental health condition that affects more than 40 million people worldwide. while bipolar disorder research has historically been underfunded, three family philanthropies recently announced they are donating $150 million to launch a new initiative known as bd2: breakthr
program overview: bipolar disorder, also known as manic-depressive illness, is a psychiatric condition that causes unusual shifts in mood state, sleep, energy, activity levels, and the ability to carry out day-to-day tasks. it alternates periods of extremely “up,” elated and...
introduction bipolar disorder is a chronic and complex disorder that can be difficult to treat. the objective of this retrospective study was to describe treatment patterns among patients with bipolar disorder. methods adults newly diagnosed with bipolar disorder from 2016 to 2018 were identified using the ibm® marketscan® commercial claims database. patients were enrolled for at least 12 months prior to and 6 months after initial diagnosis. lines of therapy (lots) were continuous treatment periods based on filled prescriptions; medications, such as antidepressants, mood stabilizers, atypical antipsychotics, benzodiazepines, stimulants, and off-label prescriptions, were recorded. all data were analyzed descriptively. results a total of 40,345 patients met criteria. the most common initial episode types were bipolar ii (38.1%), and bipolar i depression (29.8%), mania (12.8%), and mixed features (12.0%). among all episode types, approximately 90% of patients received treatment (lot1) and approximately 80% of these patients received at least one additional lot. across all episode types, the most common medication classes in lot1 (n = 36,587) were mood stabilizers (43.8%), antidepressants (42.3%; 12.9% as monotherapy), atypical antipsychotics (31.7%), and benzodiazepines (20.7%); with subsequent lots, antidepressant (51.4–53.8%) and benzodiazepine (26.9–27.4%) usage increased. also in lot1, there were 2067 different regimens. treatment patterns were generally similar across episode type. conclusions antidepressants and benzodiazepines were frequently prescribed to treat bipolar disorder despite guidelines recommending against use as frontline therapy. these results highlight the considerable heterogeneity in care and suggest that many clinicians treating bipolar disorder are not using evidence-based prescribing practices.
related news large-scale study of brain volume finds genetic links to parkinson’s disease and adhd october 21, 2024 new grant funds study on role of brain’s reward system in autism […]
bipolar disorder usually requires a long-term treatment plan often involving a range of treatment options to properly manage the condition.
new treatments for bipolar disorder are on the horizon. here’s a look at some of the latest advances, as well as experimental therapies.
background and objectives for the systematic review bipolar disorder is a serious mental illness.
the dauten family center for bipolar treatment innovation at mass general is dedicated to finding new treatments for bipolar disorder, providing high-quality clinical care and educating our colleagues, our patients, their families and the community about this disorder.
we generate breakthrough discoveries that advance scientific understanding and lead to new interventions for preventing and treating bipolar disorder.